• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

米索前列醇用于非甾体抗炎药相关胃肠道不良事件的成本效益

The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events.

作者信息

Gabriel S E, Jaakkimainen R L, Bombardier C

机构信息

Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905.

出版信息

Arthritis Rheum. 1993 Apr;36(4):447-59. doi: 10.1002/art.1780360404.

DOI:10.1002/art.1780360404
PMID:8457220
Abstract

OBJECTIVE

To compare, in a Canadian health care setting, the costs and consequences of 3 strategies of misoprostol prophylaxis for osteoarthritis patients: prophylaxis for all patients taking nonsteroidal antiinflammatory drugs (NSAIDs), for no patients taking NSAIDs, and for only elderly patients (age > or = 60) taking NSAIDs.

METHODS

We designed a decision-analysis model which incorporated costs (estimated with ulcer patient profiles and medical records), review, and probabilities (estimated from a companion meta-analysis, selected literature review, and Ontario Ministry of Health Statistics). Effectiveness was defined as the number of episodes of gastric ulceration requiring hospitalization or outpatient management that were averted by each strategy.

RESULTS

On average, prophylaxis cost an additional $650 for every additional gastrointestinal event prevented. Prophylaxis for elderly NSAID users was cost saving if the ulcer complication rate in this group exceeds 1.2%, or if either the charges for outpatient ulcer treatment exceed $2,000, or the 3-month price of misoprostol is < or = $90.

CONCLUSION

Our results demonstrate that, in this setting, misoprostol prophylaxis may be highly cost effective.

摘要

目的

在加拿大医疗环境中,比较米索前列醇预防骨关节炎患者的三种策略的成本和后果:对所有服用非甾体抗炎药(NSAIDs)的患者进行预防、对不服用NSAIDs的患者不进行预防以及仅对服用NSAIDs的老年患者(年龄≥60岁)进行预防。

方法

我们设计了一个决策分析模型,该模型纳入了成本(根据溃疡患者资料和医疗记录估算)、回顾以及概率(根据一项配套的荟萃分析、选定的文献回顾和安大略省卫生部统计数据估算)。有效性定义为每种策略避免的需要住院或门诊治疗的胃溃疡发作次数。

结果

平均而言,每预防一例额外的胃肠道事件,预防措施需额外花费650美元。如果该组溃疡并发症发生率超过1.2%,或者门诊溃疡治疗费用超过2000美元,或者米索前列醇3个月的价格≤90美元,那么对老年NSAIDs使用者进行预防可节省成本。

结论

我们的结果表明,在这种情况下,米索前列醇预防可能具有很高的成本效益。

相似文献

1
The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events.米索前列醇用于非甾体抗炎药相关胃肠道不良事件的成本效益
Arthritis Rheum. 1993 Apr;36(4):447-59. doi: 10.1002/art.1780360404.
2
Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.非甾体抗炎药长期使用者中复杂性溃疡病的预防:诺模图在成本效益分析中的应用
Arch Intern Med. 2002 Oct 14;162(18):2105-10. doi: 10.1001/archinte.162.18.2105.
3
The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.米索前列醇在预防与使用非甾体抗炎药相关的严重胃肠道事件中的成本效益。
Arthritis Rheum. 1998 Jan;41(1):16-25. doi: 10.1002/1529-0131(199801)41:1<16::AID-ART3>3.0.CO;2-4.
4
Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.米索前列醇:其用作预防非甾体抗炎药引起的胃十二指肠损伤的药物经济学
Pharmacoeconomics. 1993 Feb;3(2):140-71. doi: 10.2165/00019053-199303020-00007.
5
A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs.
Arthritis Rheum. 1994 Mar;37(3):333-41. doi: 10.1002/art.1780370306.
6
Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.非甾体抗炎药:仅对高危患者加用一种抗溃疡药物。始终限制非甾体抗炎药的治疗剂量和疗程。
Prescrire Int. 2011 Sep;20(119):216-9.
7
Use of misoprostol in the elderly: is the expense justified?米索前列醇在老年人中的应用:费用是否合理?
Drugs Aging. 1996 Feb;8(2):84-8. doi: 10.2165/00002512-199608020-00002.
8
Underutilization of preventive strategies in patients receiving NSAIDs.非甾体抗炎药(NSAIDs)使用者预防策略的未充分利用。
Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31. doi: 10.1093/rheumatology/keg495.
9
Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease.非甾体抗炎药所致消化性溃疡病一级预防策略的成本效益
J Gen Intern Med. 2000 Jun;15(6):400-10. doi: 10.1046/j.1525-1497.2000.03459.x.
10
Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding.米索前列醇预防非甾体抗炎药所致胃肠道出血的成本效益分析
JAMA. 1990 Jul 4;264(1):41-7.

引用本文的文献

1
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).欧洲抗风湿病联盟(EULAR)关于髋关节骨关节炎管理的循证推荐:EULAR国际临床研究包括治疗学常务委员会(ESCISIT)特别工作组报告
Ann Rheum Dis. 2005 May;64(5):669-81. doi: 10.1136/ard.2004.028886. Epub 2004 Oct 7.
2
Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.依托考昔与非选择性非甾体抗炎药治疗英国骨关节炎和类风湿关节炎患者的经济学评价
Pharmacoeconomics. 2004;22(10):643-60. doi: 10.2165/00019053-200422100-00003.
3
Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
非甾体抗炎药、联用预防胃肠道毒性疗法的非甾体抗炎药以及COX-2特异性抑制剂治疗类风湿关节炎的成本效益分析
Rheumatol Int. 2005 Jan;25(1):9-14. doi: 10.1007/s00296-003-0392-2. Epub 2003 Sep 12.
4
Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.从安大略省卫生部角度比较罗非昔布与非选择性非甾体抗炎药治疗骨关节炎的增量成本效益分析
Pharmacoeconomics. 2001;19(10):1039-49. doi: 10.2165/00019053-200119100-00005.
5
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.一种用于评估非甾体抗炎药(NSAIDs)、NSAIDs加胃保护剂或塞来昔布初始治疗关节炎的临床后果的框架。
Pharmacoeconomics. 2001;19 Suppl 1:33-47. doi: 10.2165/00019053-200119001-00003.
6
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.非甾体抗炎药相关胃肠道毒性的医疗资源利用及治疗成本:多国视角
Pharmacoeconomics. 2001;19 Suppl 1:17-32. doi: 10.2165/00019053-200119001-00002.
7
COX-2 inhibitors in rheumatoid arthritis.类风湿关节炎中的环氧化酶-2抑制剂
Curr Rheumatol Rep. 2001 Feb;3(1):86-91. doi: 10.1007/s11926-001-0055-9.
8
Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.对类风湿关节炎或骨关节炎患者服用非甾体抗炎药时预防性治疗预防胃病成本效益的系统评价。
Ann Rheum Dis. 2000 Oct;59(10):753-9. doi: 10.1136/ard.59.10.753.
9
The cost effectiveness of misoprostol prophylaxis alongside long-term nonsteroidal anti-inflammatory drugs. Implications of the MUCOSA trial.
Pharmacoeconomics. 2000 Mar;17(3):295-304. doi: 10.2165/00019053-200017030-00007.
10
Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease.非甾体抗炎药所致消化性溃疡病一级预防策略的成本效益
J Gen Intern Med. 2000 Jun;15(6):400-10. doi: 10.1046/j.1525-1497.2000.03459.x.